Our object, IMO, is to show LL to be a CCR5 antagonist with
Our object, IMO, is to show LL to be a CCR5 antagonist with little or no side effects. Trials might be involved or might be a Dr. JL personal connection, or might be just someone who reads Omh20 on this board, etc...
Therefore, there is no set time frame. The reason I find negative comments offensive is counter productive to our goal of getting LL known, counter productive to the "perceived value" and if it helps keep the share price down it's a real stupid move. The share price gives us more money to work with. I do not consider a low share price to be an existential threat, just a shoot yourself in foot move.
Plus, with Dr.JL taking on a new CRO and new people, just show me where the negativity is coming from, namely one piece of evidence that says we aren't moving forward. Why should I have to prove my positive outlook, which I am certain we can all agree hurts nobody, when some are taking negative shots based on nothing.
I have never seen a Mercedes salesman say, the next 18 months should be exciting, and if they do one might question if they aren't working for the another car manufacturer.
6
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Astrana Health Completes Strategic Acquisitions Astrana Health, Inc. (NASDAQ:ASTH), a prominent management consulting services provider, has successfully concluded its acquisition of several healthcare entities. This strategic move represents a significant milestone in the expansion of its operations within the healthcare management sector. The company recently finalized...
Continue Reading
Anderson & Vreeland: A Milestone Celebration Anderson & Vreeland Inc. (NASDAQ: A&V), known affectionately as A&V, proudly celebrates its 65th anniversary, reflecting on over six decades of pioneering service in the flexographic printing industry. Since launching operations in January 1961, the company has continually adapted and evolved to serve the needs of its customers...
Continue Reading
Hyatt Takes a Hit: $15.5 Million Verdict The courtroom doors swung open, and out came a staggering $15.5 million verdict against Hyatt, plastering the corporation's name across every investor's radar today. Not some chump change, I tell ya. This hefty figure stems from a case involving the tragic death of Cindy Gonzalez, a diabetic hotel guest left high and dry by...
Continue Reading
Legal Concerns Surrounding Rocket Lab USA Inc. Recent events have raised significant legal concerns for Rocket Lab USA, Inc. (NASDAQ: RKLB). The national shareholder rights law firm Bragar Eagel & Squire, P.C. is actively investigating potential claims against the company on behalf of its long-term stockholders. These inquiries stem from a class action lawsuit filed...
Continue Reading
Analyzing Market Sentiment Around Klarna Group PLC A storm’s brewing if you’re watching Klarna Group PLC's short interest data. Just to give you a pulse on the situation, short interest has spiked by 21.74% since the last report. We’re talking about a whopping 16.95 million shares sold short, which translates to 6.16% of available shares. Now, as the dust settles,...
Continue Reading